Bristol Myers Squibb (CELG-RI) Non-cash Items (2011 - 2012)
Bristol Myers Squibb (CELG-RI) posted quarterly Non-cash Items of $394.0 million for Q4 2012, down 44.03% YoY from $704.0 million in Q1 2012, and down 44.03% sequentially from $704.0 million in Q4 2011.
Bristol Myers Squibb (CELG-RI) Non-cash Items (2011 - 2012) Analysis & Trends
Bristol Myers Squibb has disclosed Non-cash Items across 2 years of filings, most recently posting $394.0 million for Q4 2012.
- In Q4 2012, Non-cash Items fell 44.03% year-over-year to $394.0 million; the TTM figure through Dec 2012 stood at $394.0 million (down 44.03% YoY), while the FY2012 annual figure was $394.0 million, down 44.03% from the prior year.
- Non-cash Items declined to $394.0 million in Q4 2012, from $704.0 million in the prior quarter.
- Over the last five years, Non-cash Items for CELG-RI reached as high as $704.0 million in Q4 2011 and fell as low as $394.0 million in Q4 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Bristol Myers Squibb | 244.56 Mn | -10.21 Bn | 8.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | 394.00 Mn |
| Dec 31, 2012 | 394.00 Mn |
| Dec 31, 2011 | 704.00 Mn |
| Dec 31, 2011 | 704.00 Mn |